Neptune Medical today announced the successful spinout of its subsidiary, Jupiter Endovascular, following the completion of a $97 million Series D financing.
This financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as chairman of the board. It will also enable Jupiter Endovascular to focus on its novel endovascular technology platform.
"Neptune Medical is thrilled to announce the successful closure of our Series D financing and the spinout of Jupiter Endovascular. These significant milestones allow us to sharpen our focus on GI robotics while empowering Jupiter to drive innovation in endovascular treatments," said Alex Tilson, Founder and CEO of Neptune Medical. "We are grateful to our investors for their unwavering support and confidence in our vision."
